Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01566773 · ClinicalTrials.gov registry record · Phase 2
PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD
A Phase 2 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT01566773 is a Phase 2 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 140 participants.
The verdict
NCT01566773, a Phase 2 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.
Interventions
- DRUG Tiotropium Bromide
- DRUG PT001 MDI
- DRUG PT001 Placebo MDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01566773
The ClinicalTrials.gov registry entry for NCT01566773 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tiotropium Bromide is the first listed.
NCT01566773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01566773 about?
NCT01566773 is a clinical study titled "PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD". The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.
What is the current status of trial NCT01566773?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2012-03. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01566773?
The interventions under investigation include: Tiotropium Bromide (DRUG), PT001 MDI (DRUG), PT001 Placebo MDI (DRUG).
Who is sponsoring clinical trial NCT01566773?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.